A research team in the United States explored the influence of vitamin D3 supplementation at 4000 IU daily for one year on the outcome of early stage, low-risk prostate cancer (Gleason score ≤6, prostate-specific antigen [PSA] ≤10, clinical stage T1c or T2a). This evidence concerns the gene KLK3 and prostate carcinoma.